Robert Lowsky
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Blood and Marrow Transplant Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 723-0822 Fax (650) 725-8950
- Academic Offices
Personal Information Email Tel (650) 723-0822Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Blood and Marrow Transplant
- Cancer> Hematology
- Blood and Marrow Transplantation
- Hematology
Professional Education
| Residency: | Toronto General Hospital, Canada (1991) |
| Board Certification: | Internal Medicine, Royal College of Physicians and Surgeons (1992) |
| Medical Education: | McGill University, Canada (1988) |
| FRCP: | Coll of Physicians/Surgs Canada, Hematology (1993) |
| FRCP: | Coll of Physicians/Surgs Canada, Internal Medicine (1991) |
| MD: | McGill University, Medicine (1988) |
Scientific Focus
Current Research Interests
Dr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
Clinical Trials
- Recruiting TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
- Recruiting Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies
- Recruiting Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)
- Recruiting Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
- Recruiting A Database Study for Hematopoietic Stem Cell Transplantation and Marrow Injuries
Publications
- Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation. Clin Immunol. 2013; (1): 124-135
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Rare cells predict GVHD. Blood. 2012; (21): 4820-1
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012; (5): 1133-45
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
Help